Introduction and WHO perspective on the global burden of musculoskeletal conditions

Rheumatology

Volumn 41, Issue SUPPL. 1, 2002, Pages 1-2

  Reginster, J Y ^a   Khaltaev, N G ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTHRALGIA; ARTHRITIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG EFFICACY; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HUMAN; MORTALITY; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; PATIENT RIGHT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK FACTOR; WORLD HEALTH ORGANIZATION;

EID: 0036105557     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/41.s1.1     Document Type: Article

References (12)

1. Management of patients with osteoarthritis
2. Les couts socio-economiques de l'arthrose en France
3. Prevalence of Arthritis-United States, 1997
4. Which chronic conditions are associated with a better or poorer quality of life?
5. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multi-disciplinary pain center
6. Persistent pain and well-being: A WHO study in primary care
7. World development report 1993: Investing in health
8. Global burden of disease and injury series, Vol. I. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020
9. NSAIDs-should every prescription carry a government health warning?
10. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
11. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
12. The coxibs, selective inhibitors of cyclooxygenase-2